Syneos Health
Syneos Health is recorded as a service provider in 653 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 653 trials · Latest update first
A Multicenter, Randomized, Double-blind, Placebo- controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis
Sponsor DICE Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study used 46 sites across Canada (10), Czechia (3), Germany (2), Hungary (3), Poland (8), Spain (3), the United Kingdom (3), and the United States (14).
- A total of 293 participants signed consent and 229 were randomized, compared with approximately 225 participants planned for randomization.
- Enrollment was geographically balanced between North America/Western Europe (53.1%) and Eastern Europe (46.9%).
These findings describe the trial, not the service provider’s performance or responsibility.
KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who have completed the pediatric ORION-16 , ORION-13, ORION-20, or ORION-19 studies (VICTORION-PEDS-OLE)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center, roll-over study to assess long-term safety in subjects who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012).
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-2)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
Sponsor 4d Molecular Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A double-blind, double-dummy, parallel-group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
Sponsor Corvus Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Sponsor Spyre Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A PHASE III, MULTICENTER, RANDOMIZED, OPEN‑LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS POLA‑R‑CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination with Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Syneos Health?
The 2026-10-09 snapshot links Syneos Health to 653 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Project management, Safety reporting & pharmacovigilance, among 160 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Syneos Health?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Immunology, Neurology, Haematological Malignancies. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Syneos Health conducted?
The linked trials record locations in 28 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where Syneos Health delivered services.
What can this page tell me about Syneos Health's trial experience?
Browse 653 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 15 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 16 recorded name variants under Syneos Health. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Syneos Health
- Syneos Health Ba Limited
- Syneos Health CZ s.r.o.
- Syneos Health Clinical Spain S.L.
- Syneos Health Clinique Inc.
- Syneos Health France S.A.R.L.
- Syneos Health Germany GmbH
- Syneos Health Hellas Single Member S.A.
- Syneos Health IVH UK Limited
- Syneos Health Inc.
- Syneos Health Italy S.r.l.
- Syneos Health Netherlands B.V.
- Syneos Health Romania S.R.L.
- Syneos Health UK Limited
- Syneos Health,
- Syneos Health, LLC